Butyrophilin subfamily (BTN) (BTN)

The Butyrophilin (BTN) subfamily comprises a group of type I transmembrane proteins within the immunoglobulin superfamily that share structural homology with the B7 family of costimulatory molecules [1, 13]. These proteins are fundamental regulators of immune responses, particularly serving as the molecular link between cellular metabolism and the activation of gamma-delta (γδ) T cells [6, 11]. The most clinically significant member, Butyrophilin subfamily 3 member A1 (BTN3A1 or CD277), functions as a sensor for intracellular phosphoantigens, such as isopentenyl pyrophosphate (IPP), which accumulate in stressed, infected, or malignant cells [2, 14]. Upon binding these metabolites through its cytoplasmic B30.2 domain, BTN3A1 undergoes a conformational change in its extracellular portion that is recognized by the Vγ9Vδ2 T-cell receptor, triggering potent cytotoxic activity and cytokine release [6, 15]. In the context of disease, dysregulation of butyrophilin expression is associated with various cancers, where they can facilitate immune evasion, and with autoimmune conditions like psoriasis and multiple sclerosis [10, 16, 19]. Therapeutic targeting of this pathway is a burgeoning area of oncology, with drugs like the agonistic monoclonal antibody ICT01 designed to activate BTN3A across all isoforms to recruit γδ T cells to tumor sites [5, 16]. Additionally, bisphosphonates such as zoledronic acid indirectly modulate this target by inhibiting the mevalonate pathway, leading to the accumulation of phosphoantigens that activate the BTN3A1-mediated immune response [15, 20]. Consequently, butyrophilins represent a unique class of metabolic immune checkpoints that offer distinct advantages for immunotherapy and the treatment of infectious diseases [8, 14].

Other names

ButyrophilinCD277BTN3ABTN1A1BTN2A1BTN3A1BTF5BT3.1Butyrophilin-3

Activation of Vgamma9Vdelta2 T cells through conformational modulation of the BTN3A1 extracellular domain, triggered either by direct agonist antibody binding or by the accumulation of intracellular phosphoantigens that bind the intracellular B30.2 domain.